Dan KidlePRINCIPAL

BIOGRAPHY

Dan identifies promising investment opportunities across Arboretum’s sectors of interest, with particular emphasis on life science tools. He also works closely with portfolio companies to support strategic decision-making, fundraising efforts, and financial analysis. Since joining Arboretum in 2011, Dan has undertaken primary due diligence responsibilities on more than a dozen of Arboretum’s new and follow-on investments including NeuMoDx, Rethink, Strata Oncology, and SI-BONE. Dan currently serves as a board director for Swift Biosciences and Dropworks and previously for IntelliCyt, which was acquired in 2016.

Prior to joining Arboretum, Dan was a Financial Analyst at Eli Lilly & Company, supporting the company’s U.S. sales and marketing operations. Dan currently serves on the Investment Advisory Board for the Monroe-Brown Biomedical Seed Fund at the University of Michigan.

Dan earned a BBA and an MBA from the Ross School of Business at the University of Michigan.

CURRENT BOARD SEATS
Dropworks
Swift Biosciences
NeuMoDx (obs)
Strata Oncology (obs)

PREVIOUS PORTFOLIO INVOLVEMENT
IntelliCyt (acquired)

ACTIVITIES AND AFFILIATIONS
Member, Wayne State M-TRAC Oversight Committee


Member, Monroe-Brown Seed Fund Investment Advisory Board, University of Michigan

ASSISTANT: Janelle Deon